0001493152-18-005907.txt : 20180430 0001493152-18-005907.hdr.sgml : 20180430 20180430061537 ACCESSION NUMBER: 0001493152-18-005907 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180430 DATE AS OF CHANGE: 20180430 EFFECTIVENESS DATE: 20180430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoverink Biotechnologies, Inc. CENTRAL INDEX KEY: 0001586494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463590875 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55055 FILM NUMBER: 18786557 BUSINESS ADDRESS: STREET 1: 1801 CENTURY PARK EAST STREET 2: 24TH FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90067 BUSINESS PHONE: 866-443-4666 MAIL ADDRESS: STREET 1: 1801 CENTURY PARK EAST STREET 2: 24TH FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90067 FORMER COMPANY: FORMER CONFORMED NAME: Hoverink International Holdings Inc. DATE OF NAME CHANGE: 20140717 FORMER COMPANY: FORMER CONFORMED NAME: Sky Run Acqusition Corp DATE OF NAME CHANGE: 20130911 NT 10-Q 1 nt10-q.htm

 

 

 

United States

Securities and Exchange Commission

Washington, D.C. 20549

 

FORM 12b-25

 

SEC File Number: 000-54830

CUSIP Number: 44248X 107

 

NOTIFICATION OF LATE FILING

 

(Check one): [X] Form 10-Q [  ] Form 20-F [  ] Form 11-K [  ] Form 10-K [  ] Form 10-D
  [  ] Form N-SAR [  ] Form N-CSR      

 

  For Period Ended: March 31, 2018  
  [  ] Transition Report on Form 10-K  
  [  ] Transition Report on Form 20-F  
  [  ] Transition Report on Form 11-K  
  [  ] Transition Report on Form 10-Q  
  [  ] Transition Report on Form N-SAR  
  For the Transition Period Ended:  

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein . If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

Hoverink Biotechnologies, Inc.

Full Name of Registrant

 

Hoverink International Holdings, Inc.

Former Name if Applicable

 

1801 Century Park East., 24th Floor

Los Angeles, California 90067

 

 

 

 
 

 

PART II — RULE 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate)

 

[X] (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
[X] (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

There will be a delay in filing the Company’s Annual Report on Form 10-Q for the period ended March 31, 2018, because the Company needs additional time to complete the report and its auditors need additional time to complete the review of the Company’s financial statements for the period ended March 31, 2018. While the Company hopes to complete and file the Report on or before the fifteenth calendar day following the prescribed due date, there can be no guarantee that it will be able to do so.

 

PART IV — OTHER INFORMATION

 

  (1) Name and telephone number of person to contact in regard to this notification

 

  Debbie Carter   866   443-4666  
  (Name)   (Area Code)   (Telephone Number)  

 

  (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
    [  ] Yes [X] No 10-K filing 2017
     
  (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
    [  ] Yes [X] No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

2
 

 

Hoverink Biotechnologies, Inc.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized. Date: April 30, 2018

 

By: /s/ Debbie Carter  
Name: Debbie Carter  
Title : CEO  

 

ATTENTION

 

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

 

3